The TVBL within Cancer Biology in the Division of Cancer & Stem Cells is a multi-disciplinary research laboratory working on biological basics of cancer and vascular biology, and how we can use this to translate new findings on mechanisms of cancer and vascular disease into novel therapeutic approaches for cancer and other diseases.

Research groups

The research in the TVBL currently includes five groups focussing on vascular biology, cancer genetics, pain mechanisms, hypoxia/acidosis, and microvascular imaging.

Group leaders

Follow us

 David Bates, Professor of Oncology

My research focusses on the biology of VEGF, regulation of angiogenesis, vascular permeability and control of splicing.

Abdol Shams Nateri, Associate Professor

Alan McIntyre, Assistant Professor

Kenton Arkill, Senior Research Fellow

The TVBL Resources.


We currently have no vacancies in the TVBL

PhD Studentships

 Click here to see opportunities. We also have self funded studentships available listed by PI.

Upcoming and recent Events

We have a dynamic and active training and social programme, including our defence of our DragonBoat race title.

Seminar Series

Recent Publications (2017)

DO Bates, N Beazley Long, AV Benest, X Ye, N Ved, RP Hulse, S Barratt, LF Donaldson, SJ Harper, M Peiris-Pages, DJ Tortonese, S Oltean, RR Foster Physiological role of vascular endothelial growth factors as homeostatic regulators. Comprehensive Physiology in press

V Pang, DO Bates, L Leach Regulation of human feto-placental endothelial barrier integrity by vascular endothelial growth factors: competitive interplay between VEGF-A165a, VEGF-A165b, PLGF and VE-cadherin. Clinical Science in press

T Sae-lao, N Luplertlop , DO Bates, K Wongprasert. Sulfated galactans from the red seaweed Gracilaria fisheri inhibit migration of cholangiocarcinoma cells (CCA). J. Phytomedicine.

Mortara L, Benest AV, Bates DO, Noonan DM.Can the co-dependence of the immune system and angiogenesis facilitate pharmacological targeting of tumours? Curr Opin Pharmacol. 2017 Jun 14;35:66-74. doi: 10.1016/j.coph.2017.05.009. [Epub ahead of print] Review.

Stevens M, Neal CR, Salmon AH, Bates DO, Harper SJ, Oltean S.VEGF-A165 b protects against proteinuria in a mouse model with progressive depletion of all endogenous VEGF-A splice isoforms from the kidney. J Physiol. 2017 Jun 2. doi: 10.1113/JP274481. [Epub ahead of print]

Betteridge K, Arkill K, Neal C, Harper S, Foster B, Satchell S, Bates D, Salmon A. Sialic acids regulate microvessel permeability, revealed by novel in vivo studies of endothelial glycocalyx structure and function. J Physiol. 2017 May 19. doi: 10.1113/JP274167. [Epub ahead of print]

T Sae-Lao, R Tohtong, DO Bates, K Wongprasert.Sulfated Galactans from Red Seaweed Gracilaria fisheri Target EGFR and Inhibit Cholangiocarcinoma Cell Proliferation.  Am J Chin Med. 2017;45(3):615-633. doi: 10.1142/S0192415X17500367. Epub 2017 Apr 6.

N Ved, RP Hulse, SM Bestall, LF Donaldson, JW Bainbridge, DO Bates Vascular endothelial growth factor-A165b ameliorates outer-retinal barrier and vascular dysfunction in the diabetic retina. Clinical Science 2017 Jun 1;131(12):1225-1243. doi: 10.1042/CS20170102. Epub 2017 Mar 24.

J Castle Miller, DO Bates, DJ Tortonese Angiogenesis dependent seasonal control of pituitary function Proc Nat Acad Sciences USA 2017 Mar 21;114(12):E2514-E2523

J Batson HD Toop, C Redondo, R Babaebi-Jadidi, A Chaikuad, SF Wearmouth, B Gibbons, C Allen, C Tallant, J Zhang, C Du, JC Hancox T Hawtrey, J Da Rocha R Griffith, S Knapp, DO Bates, JC Morris Development of novel, potent SRPK1 inhibitors by kinase insert domain interactions. ACS Chem Biol 2017 12(3):825-832

OA Stone, JG Carter, PC Lin, E Paleolog, MJ Machado, and DO Bates. Differential regulation of blood flow induced neovascularisation and mural cell recruitment by VEGF and angiopoietin signalling. J Physiol 2017 Mar 1;595(5):1575-1591

DO Bates, JC Morris, S. Oltean, LF Donaldson. Pharmacology of modulators of alternative splicing. Pharmacological Reviews 2017. Jan;69(1):63-79..

See more here


Exonate Ltd is a spin out company of the TVBL, focussed on developing treatments for diseases involving altered splicing, particularly of VEGF.


Our funding comes from multiple sources. We gratefully acknowledge funding from the following bodies

Tumour and Vascular Biology Laboratories

Cancer Biology

Division of Cancer and Stem Cells

School of Medicine

The University of Nottingham
C Floor, West Block, Queen's Medical Centre
Nottingham, NG7 2UH

telephone: +44 (0) 115 82 31135

Last edited, 17/6/2016.